The Ibogaine Dossier
NYU Conference on Ibogaine Nov 5-6, 1999
initiate Bwiti Mitsogo
photo by Gollnhofer
Robert Goutarel
Otto Gollnhofer Ethnographer
William J. Gladstone
Gladstone worked for a year in collaboration with Gollnhofer and Goutarel to render the ideas of
the authors into an original English text.
|
Main |
What's new |
Search |
Science |
Opinion |
Literature |
Art |
Links |
Treatment |
Bookshop |
Feedback
Pharmacodynamics and Therapeutic Applications of Iboga and
Ibogaine
By Robert Goutarel, Honorary
Research Director;
Otto Gollnhofer and Roger
Sillans, Ethnologists, C.N.R.S.
(French National Scientific Research Center)
(Translated from French by William J. Gladstone)
Psychedelic Monographs and Essays, Volume 6:70-111, 1993
Table of Contents
Abstract
Note on the structure of ibogaine
History (1864-1905)
Therapeutic applications
Pharmacodynamics (1939-1950)
Therapeutic application: Lambarène,
1939-1970
Pharmacodynamics (1950s-1970s)
1970s-1990
The Gabonese rituals of iboga: Bwiti of the Mitsogho
Bwiti of the Fang
Ibogaine in psychotherapy: psychoanalysis according to Naranjo
Ibogaine for combatting drug dependencies according to Howard Lotsof
Conclusions
Near Death Experiences
Interviews with young Frenchmen
Bibliography
Robert
Goutarel (bio)
Abstract
Tabernanthe iboga H.Bn. is
an apocynaceous shrub from Equatorial Africa whose roots are used in Gabon
at low doses as a stimulant and at high doses during the ceremony for
admission into the Gabonese initiation society, the Bwiti. Four periods are
described: the first three relate to the pharmacodynamic studies conducted
in France (1864-1905; and 1940-1950) and subsequently in the U.S.A.,
essentially Ciba's work (1950-1970). The low acute and chronic toxicity of
ibogaine is established (Dhahir, 1971). Ibogaine inhibits the oxidation of
serotonin and catalyzes that of catecholamines by a MAO (monoamine
oxidase), ceruloplasmin (Barrass and Coult, 1972).Ibogaine is a type of
hallucinogen (oneirophrenic) at high doses.
The present period
began around 1960 and covers the applications of ibogaine in psychotherapy
and psychoanalysis according to Naranjo (1960) and in combatting drug
dependency according to Howard S. Lotsof. The role of iboga in Bwiti
initiation ceremonies was studied by ethnologists in Gabon. The
intoxication by iboga (chewing) is slow and progressive and is
characterized by four stages of oneiric manifestations. The first three
stages are essentially Freudian; the fourth one, called the stage of
normative visions, corresponds to the collective image of the tribe,
visions of the beyond and of spiritual entities, Masters of the Universe.
The initiate will see the Bwiti only twice during his life, on the day of
his initiation and on the day of his death, which means that the normative
visions have some similarities to the near death experience (NDE). The
psychotherapeutic method of Naranjo involves only the Freudian stages
produced by subtoxic doses of ibogaine, while H.S. Lotsof goes beyond that
stage to reach another one comparable to the normative visions or NDE,
bringing about the cure of addicts.
Based on recent
"neuroscientific" evidence concerning the mode of action of ibogaine, the
National Institute on Drug Abuse (NIDA) has added ibogaine to the list of
drugs whose activity in the treatment of drug dependency is to be
evaluated. Ibogaine blocks the morphine- and cocaine-induced stimulation of
mesolimbic and striatal dopamine and reduces the intravenous
self-administration of morphine in rats. Return to table of contents
Note on the structure of ibogaine
Chemical investigations for the purpose of establishing the structural
formula of ibogaine were undertaken by two groups: a Swiss group headed by
Professor E. Schlittler (Organisch chemische Anstalt der Universität
Basel), and a French-Swiss research group including Professor V. Prelog,
Nobel laureate in chemistry (Zürich Federal Polytechnic School),
Professor M.M. Janot (School of Pharmacy, Paris), and R. Goutarel.
The discovery of ibogamine, a nonoxygenated alkaloid, the basis of the
other iboga alkaloids, was published jointly by C.A. Burckhardt, R.
Goutarel, M.M Janot and E. Schlittler (Helv. chim. Acta, 35, 1952, p.
642).8
Using the alkaline fusion of
ibogaine, Schlittler's group isolated 1,2-dimethyl-3-ethyl-5-hydroxyindole
(Schlittler, E., Burckhard, C.A., Gellert, E., Die Kalischmelze des
Alkaloides Ibogain, Helv. chim. Acta, 36, 1337, 1953)50, while the French-Swiss group (Structure de
l'ibogaïne, R. Goutarel, M.M. Janot, F. Mathys and V. Prelog, C.R.
Acad. Sci., 237, 1953, p. 1718)26 characterized
3-methyl-5-ethylpyridine.
The combination of these results led R.
Goutarel to propose, in 195425, a formula that included all the elements of
the structure of ibogaine; the definitive structure necessarily had to
include a fifth ring formed by a bond between the C-17 or a carbon atom
from the ethyl chain and another carbon atom of this molecule (most likely
C-16).
The definitive structural formula was established by W.I.
Taylor (Bartlett, M. et al., 1958)3 in which
ibogaine has an ethyl chain, following the study of the seleniated
dehydrogenation products of this alkaloid.
W.I. Taylor had
belonged to the French-Swiss group before he joined Prof. Schlittler's
staff at Ciba Laboratory in Summit, New Jersey, and contributed in
particular to the study of cinchonamine and quinamine (R. Goutarel, M.M.
Janot, V. Prelog and W.I. Taylor, Helv. chim. Acta, 33, 1950, p. 150,
164).27
"Clinical research, the
one which is directly concerned with human illness, will be the bearer of
great hopes." *
*Philippe Lazar, Director General of INSERM (French
National Institute of Health and Medical Research), Madame Figaro, No.
14110, 88 (1990) Return to table of contents
History (1864-1905)
The
pharmacodynamic and clinical research on iboga and ibogaine may be divided
into four periods. Henri Baillon, who established the genus
Tabernanthe H.Bn. at the Muséum d'Histoire Naturelle in Paris
in 1889, and described under the name of Tabernanthe iboga H.Bn. the
sample*brought back from Gabon in 1864 by Dr. Griffon du Bellay, a navy
surgeon, wrote: "The root of this plant is the part that the Gabonese eat.
They say that it is inebriating, aphrodisiac, and, with it, they claim that
they feel no need for sleep".1 However, as
early as 1885, Father Henri Neu had written in a manuscript entitled "Le
Gabon" (Neu 1885)42:
"Most Europeans
(living in Gabon) have heard about this plant, used in fetishistic
ceremonies. The natives use an infusion of iboga root scrapings as a potent
philter that enables one to discover hidden things and to tell the future.
The one who drinks it falls into a deep sleep during which he is obsessed
by uninterrupted dreams which, until the time that he awakens, he takes to
be actual events..."
At the beginning of this century, Dybowsky and
Landrin (1901)17 isolated a crystallized
alkaloid from the iboga roots and named it ibogaine.
*This sample,
along with the roots, was displayed at the Paris Exposition in 1867, and
had been reported earlier by Aubry-Lecomte ("Note sur quelques poisons de
la côte occidentale de l'Afrique, Archives de Médecine navale,
2, 1864, p. 264-265). It was then given to the Paris Muséum
d'Histoire Naturelle. Return to table of contents
Therapeutic
applications
The first step in the pharmacodynamic studies began when Phisalix
(1901)43 showed that, in the dog, this alkaloid
acts principally on the CNS and produces inebriation similar to alcoholic
drunkenness (though this would be contradicted later).
This was
the period of studies by the French pharmacologists, Lambert, (1901)30, (1902) 31 Heckel,
(1901)28 and Pouchet, (1905).44 The results were
that ibogaine, used clinically, was recommended as a stimulant in cardiac
"atony" and neurasthenia by Pouchet and Chevalier (1905). 44
This period ended in 1905 with the thesis for a medical degree, "De
l'Iboga et de l'ibogaïne" (de Closmenil 1905)9, defended in Paris by Mme de Closmenil, the
daughter of Landrin, who advocated the use of ibogaine hydrochloride at
doses of 10-30 mg/day in convalescence, neurasthenia and asthenia.
Thus, it was the "antifatigue" properties of ibogaine that particularly
attracted the attention of investigators of this period, and another 40
years were to pass before the study of this alkaloid was resumed.
Return to table of contents
Pharmacodynamics (1939-1950)
In 1941, Raymond-Hamet 48 published a paper entitled "L'iboga, drogue
défatigante mal connue" (Iboga, a poorly known antifatigue drug), in
which he showed that ibogaine increases the responsiveness of animals to
epinephrine and puts the organism in a state of hypersympathicotonus, and
he would later refer to it as a "sympathicosthenic" agent, in contrast to
yohimbines which, according to him, were "sympathicolytics".
During the same period, Delourme-Houdé prepared a remarkable
thesis for a doctorate of pharmacy which he defended after the war was over
in France in 1944. In this thesis, he discussed the botany, chemistry, and
pharmacodynamics of iboga. He also isolated a new alkaloid which he named
tabernanthine (Delourme-Houdé, 1944).13
Delourme-Houdé determined the LD50 of ibogaine in the
guinea pig intraperitoneally to be 82 mg/kg.
In 1941, Raymond-Hamet had demonstrated the
"sympathicosthenic" activity of ibogaine and the fact that this alkaloid
suppressed the hypertensive effects produced by carotid occlusion, that it
increases tyramine-induced hypertension, and he further demonstrated its
own hypotensive action, confirmed by Miss Séro (1944)55. He showed that ibogaine acts as a true
antagonist of "sympatholytics" (Raymond-Hamet 1939-1946). 47
Vincent and Miss Séro, of
Montpellier, demonstrated the inhibitory action of iboga on serum
cholinesterase (Vincent, D. and Séro, I. 1942).56
Previously, in 1939, Wurman
(1939)57. had published a Doctorate of Medicine
thesis in Paris, entitled "Contribution à l'étude
expérimentale et thérapeutique d'un extrait de T. manii (syn.
T. Subsessilis), d'origine gabonaise" (Contribution to the experimental and
therapeutic study of an extract of T. manii [syn. T. subsessilis] from
Gabon).
This extract reportedly contained about 6%
total alkaloids including 4% ibogaine, as determined by the assays of
Raymond-Hamet. According to Wurman, this extract
stimulates hematopoiesis in the mouse and has a hypotensive action.
Return to table of contents
Therapeutic application: Lambarène,
1939-1970
It was during this period, in 1939, that a proprietary
pharmaceutical preparation called Lambarène in honor of Dr.
Schweitzer, was first marketed in France: it was based on a dry
pharmaceutical extract of roots of Tabernanthe manii, with a drug content
of 0.20 g of extract per tablet (about 8 mg of ibogaine), whose therapeutic
action, dosage regimen and effects were, according to package information,
as follows: "a neuromuscular stimulant, promoting cell combustions and
getting rid of fatigue, indicated in cases of depression, asthenia, in
convalescence, infectious diseases, greater than normal physical or mental
efforts by healthy individuals. 2-4 Tablets daily. Rapid and prolonged
action, not followed by depression. May be administered to
hypertensives."
The fact that it was recommended for physical or
mental efforts by healthy individuals rapidly aroused the interest of
post-war athletes (Paris-Strasbourg walking race competitors, mountain
climbers, cyclists, cross-country runners, etc.).
Haroun Tazieff,
elebrated French geologist and volcanologist, Honorary Research Director
at the C.N.R.S. gave the following description of his experience with
Lambarène in his book, "Le gouffre de la Pierre Saint-Martin"
(Arnaud publ.).
"Go ahead", said André (the expedition's
doctor), "it will give you strength. And also swallow this, he
added as he handed me a tablet.
Do you think we should already be
taking this? Shouldn't we save it until we are completely exhausted?"
It was Lambarène, a stimulant, a "doping" agent which was
supposed to enable us to find the necessary strength in our exhausted
bodies.
"No, go ahead, what we have to do is to prevent fatigue.
Later on, we'll be taking some more, regularly..."
We had just
swallowed our third tablet of Lambarène, and we could feel a tonic
effect.
I hastened, "doped up" on Lambarène, and jumped
from one boulder to the next with renewed agility...
Despite the
Lambarène, I was really beginning to feel worn out and had trouble
scaling the huge boulders which we immediately had to descend to start on
the next one, while insidious cramps crept along the anterior portions
of my thighs.
I was hoping they wouldn't get worse...
I took
another Lambarène. While André climbed up the ladder, I
massaged my legs. Within ten minutes, everything was in order and in turn I
climbed up without any difficulty...
In spite of the fact that I
had swallowed a Lambarène, I really didn't feel talkative at all.
Time flowed on, like a stream. One hour passed, and so did the effect of
the Lambarène..."
And, on this last day, this frenzied race
toward our discovery, these six hours of descent and climbing sustained by
Lambarène, this day on top of all others, it was
terrible... Only the stimulant enabled us to keep going. When the
effect of the last tablet had passed and I had no more, I was nothing but a
pitiful package of meat miserably dangling at the end of a wire"
Lambarène disappeared from the market around 1966 and the
sale of ibogaine was prohibited. Since 1989, this alkaloid has
been on the list of doping substances banned by the International Olympic
Committee, the International Union of Cyclists and the French State
Secretariat for Youth and Sports. Return to table of contents
Pharmacodynamics (1950s-1970s)
The 3rd period covers the
time of the discovery of reserpine in the Rauwolfias by Schlittler
(Mueller, J.M., Schlittler, E., Bein, H.J. 1952)40, which prompted a new interest in plants
containing indole alkaloids. French chemists were outstanding in
this field by virtue of their discovery of new indole alkaloids and by
establishing their structures, but we must say that foreign pharmacologists
were mainly responsible for the new research on the pharmacodynamics of
Iboga.
A description of these investigations can be found in the
PhD thesis of Dhahir (1971)14, and in an
article by J. Delourme-Houdé which was published in Fitoterapia
(Delourme-Houdé 1977).19
Structurally, ibogaine is a derivative of serotonin and an indole
azepine.25 It was this comparison with serotonin that was the main subject
of Dhahir's thesis (1971).14 In this thesis
at the Department of Pharmacology and Toxicology of the University of
Indiana in 1971, Dhahir established the acute and chronic toxicities of
ibogaine: The intragastric LD50 in the rat is 327 mg/kg. The
intraperitoneal LD50 in the rat is 145 mg/kg.
The mouse and the
guinea pig are more sensitive than the rat. The toxicity is not changed by
the ingestion of 1 g/kg of alcohol. Alcohol suppresses tremor in the animal
as a result of its depressant effect on the CNS which attenuates the
stimulant effects of ibogaine.
Therefore, the inebriation in the
dog reported in 1901 by Phisalix is not comparable to alcoholic
inebriation. Larger quantities of alcohol (2 g/kg) slightly
increase the toxicity of ibogaine.
Atropine sulfate at doses of
1-2 mg/kg does not affect the toxicity of ibogaine but does away with the
ataxia, tremors and most of the external signs of intoxication.
The study of chronic toxicity shows that when ibogaine was administered
for 30 days at a dose of 10 mg/kg i.p., it caused no liver, kidney, heart
or brain damage.
The administration of 40 mg/kg for 12 days to 10
rats produced no pathological changes in the liver, kidneys, heart or
brain.
This is in contrast with the toxicity of serotonin which,
at doses four times lower, causes serious damage to the kidneys: tubular
dilatation and degeneration and the presence of eosinophils.
Thus, ibogaine appears to be a relatively nontoxic
alkaloid, particularly by oral administration, with a wide therapeutic
index ranging from 10 to 50 mg as an antidepressant in humans and, as we
shall see later, from 300 mg to 1 g when used for its oneiric action, the
toxic doses being similar to those of aspirin and quinine.
Schneider and Reinehart (1957)51 analyzed
the cardiovascular effect of ibogaine hydrochloride in the dog and the cat
and showed that at doses of 2 to 5 mg/kg, ibogaine exerts negative
chronotropic and inotropic effects.
The slowing of the cardiac
output is responsible for the drop in blood pressure. These effects are
suppressed by atropine. Gershon and Lang (1962)20 suggested that the changes in the
electrocardiogram of the unanesthetized dog indicate that ibogaine enhances
sinus arrhythmia and potentiates the vagal effects. They confirmed what had
been pointed out by Raymond-Hamet: ibogaine potentiates hypertension
produced by epinephrine and norepinephrine.
They pointed out that
the negative chronotropic activity of indole alkaloids is increased by the
introduction of a methoxyl group on the indole ring. Zetler and
Lessau (1972)58 synthesized two azepino-indoles
and compared them with four indole alkaloids. These compounds have direct
noncholinergic effects with negative chronotropic and inotropic
actions.
Neuropharmacological studies were carried out by
Schneider and Sigg(1957)52 using isolated cat
brain preparations, as well as curarized cats and dogs.
The
electroencephalogram shows a typical arousal syndrome when 2 to 5 mg/kg of
ibogaine hydrochloride are given intravenously. They suggested that the
site of action of ibogaine must be in the ascending reticular
formation.
Pretreatment with atropine (2 mg/kg) blocks this
ibogaine-induced arousal. There is no effect on neuromuscular
transmission. Numerous researchers were interested in the tremor
produced by certain indole alkaloids, particularly ibogaine. This tremor is
of central origin and is suppressed by atropine.
In addition,
Schneider explained the morphine-potentiating effect of ibogaine by its
inhibiting action on cholinesterase.53
Finally, in 1972, in a study on the effects of some CNS-active drugs
that can interact with ceruloplasmin, Barrass and Coult (1972) 2 indicated that at a concentration equal to that
of the substrate, ibogaine inhibits 50% of the oxidation of serotonin and
catalyzes the oxidation of catecholamines (200%) by the copper-containing
plasma globulin. They classified ibogaine among the hallucinogens
and noted that LSD produces the same effects at a concentration 10 times
lower.
It should be noted that Naranjo
(1969)41 explained the antifatigue and
antidepressant properties of ibogaine by defining it as a monoamine oxidase
inhibitor (MAOI).
We should add that more recently in France,
Wepierre45 studied the influence of
tabernanthine, an isomer of ibogaine, on the kinetic parameters of the
turnover of cardiac norepinephrine in the hypoxic rat. This hypoxia can
serve as a model to assess the protective action of this substance against
fatigue.
In addition, at Gif-sur-Yvette, in the CNRS Laboratory of
Physiology of the Nervous System, Dr. Naquet demonstrated that in the cat,
tabernanthine produces a calm and prolonged wakefulness, very different
from the one produced by amphetamines. This wakefulness is followed
by slow sleep without the anomalies that occur in REM sleep, the period of
dreams (Da Costa, L., Sulklaper, I., Naquet, R., 1985).11 Return to table of contents
1970s-1990
This previous third period lasted about 25 years.
It was not until the fourth period, which runs from the 1970s to the
present, that knowledge was acquired, sometimes illegally, into the nature
of the oneiric effects in humans of iboga and ibogaine, on the one hand
through the remarkable studies in the field by the CNRS ethnologists O.
Gollnhofer and R. Sillans and by the ORSTOM (Office of Overseas Scientific
and Technical Research.) ethnologist J. Binet, concerning the Mitsogho
Bwiti and its extension to the different Bwitis of the Fang (Gollnhofer, O.
and Sillans, R., 1985; Gollnhofer, O. and Sillans, R., 1983; Binet, J.,
Gollnhofer O., Sillans, R., 1972)23,24,4, and on the other hand through the researches
conducted in Chile by Claudio Naranjo (1969)41,
and in North America by Howard Lotsof (1985, 1986, 1989, 1991).32-37 Return to table of contents
The Gabonese rituals of
iboga:
Bwiti of the Mitsogho (4,23,24)
The original Bwiti or Bwiti
of the Mitsogho arose among the Mitsogho when they reached the territory
that is now Gabon. In the remote period, the Bwiti itself was a product of
a syncretism made up of ancestor worship enhanced by the discovery of iboga
(perhaps imparted by the Pygmies of the equatorial forest) and of cultural
elements acquired during the migrations of the Mitsogho.
Among the
Mitsogho (and the Bapinzi), the Bwiti is strictly for males, and those who
have been initiated are considered as Masters and sole custodians of the
mystery of the visual knowledge of the beyond given to them by
iboga, the "miraculous tree".
This initiation is indispensable for
social promotion within the tribe and any individual who is unable to joint
the Bwiti becomes an outcast and is considered by one and all as a
girl.
Iboga brings about the visual, tactile and auditory
certainty of the irrefutable existence of the beyond. Through his spiritually immutable substance, man belongs
on two planes of existence with which he blends, knowing not where birth
and death begin. Physical death loses all meaning because it is nothing but
a new life, another existence. "It is Iboga that conditions the several
existences."
Iboga does away with the notion of time, the present,
past and future blend into one, as in the superluminous universe of
Régis and Brigitte Dutheil16: through
the absorption of iboga, man returns to the birthplace whence he
came.
In order to be admitted to the Bwiti Society, the candidates
must submit to a series of trials or rites of passage that begin in an
enclosure strictly reserved for the initiates.
Each candidate has
a "mother", who is an old initiate; this is a man who sees to it that the
initiatory ceremony is conducted properly.
This ceremony consists
essentially of ingesting scrapings of iboga root (Tabernanthe iboga H.Bn.
var. ñoke and mbassoka).
This "chewing of iboga" is
supervised by the "mother" who constantly checks the dosage of the drug
according to the physiological reactions of his candidate who must take a
very large quantity of root bark and stems of T. iboga.
This
chewing is preceded by abstinence from sex and food the day before. The
rite is very strict and each manifestation has great symbolic value.
Over a fire, the elders roast squash seeds. The sound they make as they
pop symbolizes the release of the spirit -- which supposedly leaves the
body through the fontanelle -- on its mystical journey. The candidate's
skull is struck three times with a hammer to help free his spirit.
The neophyte's tongue is pricked with a needle to give it the power to
relate the visions to come.
Since the chewing can last several
days, the disincarnation and the reincarnation of the neophyte are
reenacted before the visions appear.
The candidate is led to the
river, and a miniature dugout canoe made of a leaf, bearing a lit torch of
okoumé resin, is set upon the waters. This rite represents the
journey of the spirit, downstream, toward the West, the setting sun, death,
and symbolizes disincarnation.
A stake surmounted by a
diamond-shaped wooden structure is planted in midstream: it represents the
female sexual organ, which the candidate must go through (in a fetal state)
against the current, thus swimming upstream, from the East, the rising sun,
from birth.
For the enactment of this initiatory birth, the
neophyte's head is shaved and is sprinkled with a red wood (padouk), as is
done with the newborn.
Finally, as soon as the neophyte's
psychological state after the chewing is considered satisfactory, he is led
into the Temple where he is placed on the left side, symbolizing womanhood,
darkness, death. He remains in the Temple, on the left side,
absorbing iboga leaves until the normative perception of the visions
occurs.
During the chewing, the effects of the drug begin to be
manifested twenty minutes after the first absorption of iboga by violent
and repeated vomiting: "The belly of the neophyte (banzi) is emptied even
of its mother's milk."
To go to the beyond, one has to die; the
body remains on the ground with the elders, the soul departs.
The
physiological manifestations begin with drowsiness, followed by motor
incoordination, strong agitation, tremor, crying and laughter, partial
anesthesia with intermittent hypothermia and hyperthermia, panting that may
go as far as choking.
To assess the progress of the intoxication
and to adjust the dosage, those in charge take the pulse, listen to the
heartbeat, check the temperature simply by touching the body and evaluate
sensibility by pricking with a needle at different times. According to the
physiological state, the "mothers" regulate the dose of iboga up or down
from time to time.
The oneiric effects do not begin to be
manifested until after about ten hours, during which time the
aforementioned rituals take place, partly in public with dances and
music.
Among the Mitsogho, the subjects under the influence of
iboga go through four stages to reach an image content corresponding to the
required norms. The candidates are constantly questioned by the initiated
elders as to the content of what they perceive. The elders are the ones who
make a judgment as to the initiatory value of the vision described.
The first vision consists of hazy, incoherent, disordered images devoid
of religious significance, whose authenticity is often questioned by the
neophyte.
The second stage is characterized by a series of apparitions
of menacing looking animals that sometimes break apart and at times form
together again rapidly.
In the third stage, the oneiric vision
clearly progresses toward the mythical stereotype. The neophyte grows more
and more calm, a sign of a pleasant, peaceful vision that dispels his
doubts as to the objectivity and factualness of the image perceived.
The neophyte feels himself enveloped by a wind that carries him off in
the twinkling of an eye, to the sound of the Ngombi harp, to an immense
village without a beginning or end.
We ought to say a word about
the symbolic value of the musical bow whose melodious sounds accompany the
ceremony. It represents a link between the village of the men here on earth
and the village of the father in the beyond. The musical bow symbolizes the
road of life and death.
On the way over, voices are heard: "Who is
it that you seek, stranger?" And the traveler answers: "I seek the Bwiti."
The voices suddenly take on human forms that ask the question again and
then respond in a chorus: "You are looking for the Bwiti. The Bwiti is us,
your ancestors, we constitute the Bwiti."
The vision tends more
and more to become normative. The initiates then tell the candidate: "You
are on the right path, the Bwiti will soon be here. Go further on. Look,
and you will find it. You must not forsake the images; take up where you
left off."
A voice gives the candidate his initiatory name. The
neophyte is watched constantly by his "mother", who regulates his
psychophysiological reactions to prevent him from letting terrifying
phantoms interfere, for they would lead him down the wrong path, down the
road of death.
The fourth stage, of vision (the one that
ethnologists refer to as the stage of normative visions) is the one marked
by the encounter with higher spiritual entities.
After a dialogue
with his ancestors, the neophyte suddenly finds "his legs immobilized,
before two Extraordinary Beings" who disclose that he is in the "Village of
the Bwiti" (village of the dead). They ask him why he has come to this
place.
After hearing the answer of the neophyte, the "Fantastic
Beings" speak again. The first one says: "My name is Nzamba-Kana, the
father of humankind, the first man on earth", and the one standing to his
left says: "My name is Disumba, the mother of humankind (wife of
Nzamba-Kana) and the first woman on earth."
Suddenly, the "Village
of the Dead" is covered with increasingly intense sparks, a "ball of light"
takes shape and becomes distinct (Kombé, the sun). This ball of
light questions the visitor as to the reasons for his journey. "Do you know
who I am? I am the Chief of the World, I am the essential point!" This is
my wife Ngondi (the moon) and these are my children (Minanga) the stars.
The Bwiti is everything you have seen with your own eyes."
After
this dialogue, the sun and the moon change into a handsome boy and a
beautiful girl. Without any warning, the moon and the sun resume
their original forms and disappear. The thunder (Ngadi) is heard and calm
returns everywhere.
The wind wraps around the neophyte for a
second time and carries him to earth among the living.
The elders
greet him with pride: "He has seen the Bwiti with his own eyes", and invite
him to take his place on the right side of the Temple, the side of men and
of life.
The candidate has become an initiate by
discovering the Bwiti in another reality, that is, in the other life
stemming at once from physical death and initiatory death.
Through
the waking dream, he catches a glimpse, in the present, past and future of
his own being, of man, immutable in his spiritual essence, and living on
two planes of existence.
However, after the rites of passage, the
new member will be isolated from the outside world for a period of one to
three weeks. During this time, his meals will be prepared and served by a
young woman who has recently given birth, because he is considered as a
newborn.
The initiate has seen, he knows, he believes, but as a
Mitsogho, he will only make this journey twice: during the initiation and
on the day of his death. It is out of the question for him to take iboga
again under the same conditions.
From then on, the sacred plant
will only be used sparingly, to "warm the heart" and to help him "in
physical efforts or discussion."
We can learn several things from
this study of the Mitsogho Bwiti.
First of all, there are some
striking similarities between the Bwiti initiation and the freemasonery
initiation rites. The end result is the same, the knowledge of the
mysteries of the beyond, which the masons call the "sublime secret".
Freemasonry initiation is preceded by the candidate's retreat during which
he is assisted by one who has been previously initiated. The latter will
convey to him, as he makes him pass through a narrow door, that the
initiation is a new birth.
But most astonishing, in the masonry
ritual, are the three blows on the head with a mallet, in remembrance of
the assassination of Hiram, the architect of the Temple of Solomon, by
three of his companions to whom he refused to reveal the "sublime secret".
The only difference between the masons and the followers of the Bwiti is
that the latter have the certainty of knowing this secret.
The
Bwiti initiation, among the Mitsogho, concerns essentially the passage from
adolescence to manhood, hence the necessity of eliminating the epigenetic
elements of childhood and adolescence in order to reprogram in the young
man a new ego corresponding to the cultural norms of the tribe.
To
achieve this, the Mitsogho call on the instrumental deprivation of sleep,
as the initiation lasts for days without sleep or food, as well as on
pharmacological deprivation through the chewing of iboga.
The
result is a waking dream without psychotic manifestations during which the
subject remains perfectly conscious and can communicate with those around
him, being at once an actor and a spectator of his visions.
What
is remarkable is the fact that iboga intoxication is very gradual, which
makes it possible to observe several stages during these visions.
Ethnologists were able to follow in the field the progression of this
intoxication and to distinguish four characteristic stages during the
initiation.
In the first three stages, the visions correspond
essentially to what the psychoanalysts call the subterranean world of
Freud.
The fourth stage is referred to by the ethnologists as the
stage of normative visions corresponding to the collective and cultural
image of the tribe (cf. Jung).
While, in the Bwiti ritual, we did
not fail to bring out certain similarities between the Bwiti initiation and
the Freemasonry initiation, we are compelled likewise to draw analogies
between certain aspects of the vision resulting from the absorption of
iboga and what certain persons see at the time of clinical death. We have
discussed this topic in the conclusions.
The neophyte will have to
face initiatory (or real) death that will enable him to gain access to the
things of the beyond.
He can do so only if he has been properly
prepared and, especially, if his motivation is sufficient.
For
various reasons - poor preparation, inadequate motivation, fear, psychosis,
neurosis - certain subjects are unable to get past this critical phase.
They fall prey to evil genies who veer them off onto the road of
death.
The elders will then decide to stop the initiation by means
of an antidote whose composition is not known. We should note that the
pharmacology of ibogaine has shown that atropine (an acetylcholine
antagonist) suppresses all signs of ibogaine intoxication as well as
ibogaine's arousal and inotropic activities.
The Ombudi (or
Ombwiri, among the Fang) is an initiatory order reserved for women who
belong to the therapists among the Mitsogho and the Fang.
The
women take iboga in smaller quantities than the ones taken in the Bwiti
initiation. In their case, the visions do not go beyond the third
(Freudian) stage during which genies, good or evil, communicate to the
women that they are in possession of the causes of the affliction or
illness for which they were consulted.
Return to table of contents
Bwiti of the Fang
(Gollnhofer, O. & Sillans, R. 1985; Gollnhofer, O. & Sillans,
R. 1983; Binet, J., Gollnhofer, O., Sillans, R.
1972)23,24,4
Along the
coastal portions of Gabon, the Bwiti began to be known by the Fang at the
time that of the explorations of Savorgnan de Brazza, but according to a
letter from Lucien Meyo, secretary of the Prophet Ekang Nwa, "it was in
1908 that the Itsogho and Bapinzi arrived in Gabon, that is to say, in the
Libreville estuary. That is where they taught the Fang how to eat iboga by
the root." Prior to that time, the Fang used the leaves of iboga and of
alan (Alchornea floribunda, an euphorbia from which Mrs. F. Khuong-Huu29 isolated a new alkaloid, alchorneine, but only
the effects of iboga roots ultimately produce the visions of the
Bwiti.
The Bwiti of the Fang, unlike that of the Mitsogho, accepts
women as members, but all of them, regardless of sex, are admitted only
after taking iboga.
The iboga root is absorbed not only in the
form of fine scrapings but also in a preparation made of cane juice or
sugar, palm wine or milk. While the extraction of iboga root is reserved
for the men, the "galenic preparations" are made by the women and are
referred to as "express" or "automatic".
Such preparations, which
reduce the bitterness and partly prevent the vomiting, make it possible to
achieve the phase of normative visions more rapidly.
During the
rites of passage, the essential features of the Mitsogho rites are
preserved and the ritual language is Mitsogho. However, the
"mother" is a woman, sometimes accompanied by her husband, who becomes the
"father".
Great importance is given to the retreat and to the
confession that precede the initiation.
The notion of purity is an
obsession in the Fang mentality, and the chewing is perceived as a trial
that serves to expiate (by vomiting) the wrongs that have been
committed.
The Fang Bwiti is actually the result of an adaptation
of the original Bwiti of the Mitsogho to the traditional ancestor worship
(Byeri), with the integration of Christian elements and concepts.
As a result, the Fang Bwiti is not uniform and is
structured through many branches that are independent from each other, in
the midst of which "prophetic and messianic movements" flourish.
According to Michel Fromaget (1986)18,
Chairman of the Department of Psychology of Libreville University from 1981
to 1983, there are two sorts of Bwiti in Gabon.
The Bwiti of the
Mitsogho which has been preserved in a very sober, refined form close to
the original model, the initial Bwiti or Disumba Bwiti, from the name of
the first woman, which has two variants:
The Mitsogho Bwiti of the
nganga-a-misoko, seers and divining sorcerers, eminent therapists who
practice psychosomatic healing and a sort of psychoanalysis.
The
N'dea Bwiti, a cult of sorcerers, a deviation from the Mitsogho Bwiti with
human sacrifices and cannibalism, whose ultimate goal is magic, the
securing of supernatural powers.
The Fang Bwiti, received
mediately at a late period by the Fangs, is an astonishing syncretism with
a blend of Christianity and animism. Bureau (1972)7 mentions 12 subdivisions in the Fang Bwiti.
Therefore, we must give up any thought of studying the Fang Bwiti as a
uniform, homogeneous entity, and it would be illusory and inaccurate to try
to look for a "normative Fang vision" comparable to the Mitsogho
Bwiti.
Therefore, within a community in which the initiation is to
take place, everything depends on the relationships that are accepted in
that community between the worship of the ancestors (represented by their
skulls), the original Bwiti, and Christianity.
If we compare, in
broad terms, the Fang Bwiti and the original Bwiti, we find striking
similarities between the contents of the vision. Only the setting and the
figures or persons represented differ. The latter are entities derived from
Christianity and may appear in unlimited numbers.
However, it
would be a mistake to think that the Fang Bwiti has departed completely
from the original Bwiti and from the ancestral culture of the Fangs. The
elements are in there, but are not very apparent. However, they can be if
we know the connection between the figures that are recognized and those
that are concealed behind them.
A Christian religious figure may
incarnate at the same time several Fang spiritual entities, and vice
versa.
During the rites of passage, we find the same
psychophysiological effects as the ones observed among the Mitsogho.
After a long series of episodes, during his mystical ascension, the
subject under the influence of iboga at its peak feels "as if transported
by the wind" to the beyond before the house of Christ and of God. He is
guided to that place by the ancestors, to the sound of the harp.
A
voice gives him his initiatory name and tells him how much money he will
have to pay to be initiated.
During his journey, he sees many
saints, Noah, priests in their cassock. Christ, dressed in gold garments,
questions the stranger as to the reason for his visit. And the neophyte
answers: "I am seeking, I want to see the Lord Jesus Christ". "I am the one
you seek", Christ replies.
From one neophyte to the next, the
content of the narratives describe encounters with Christ in some other
setting.
The subject first goes through "purgatory, where men
suffer", then on to heaven with its seven planes where angels glide. At the
highest plane, the traveler sees a man bearing a cross, and further on the
beard of God the Father.
In other visions, the Virgin Mary, Adam,
and Lucifer appear.
The dialogue is practically identical in each
vision with the dialogue reported among the Mitsogho.
In this
syncretism, Nyingon (the female principle or the first woman, called
Disumba among the Mitsogho) is assimilated both to Eve and to the Virgin
Mary.
As for Nzame, the male principle, the first man, or
Nzamba-Kana among the Mitsogho, he is represented by Jesus Christ.
To certain prophets, Adam and Christ personnify Ngoroyo-Ama, that is to
say, the "Supreme Being", who is never perceived in the Mitsogho
vision.
Lucifer, the rainbow-serpent, is present in the Fang
vision. He represents evil, that is, Evus, a well-known notion among the
Fangs.
In their lifetime, the Fang can make several journeys under
the ritual conditions of the Bwiti, enabling them to confirm the reality of
their visions. The initiates may also belong to the Ombwiri possession
society (reserved for women and called ombudi among the Mitsogho). This
society, which plays a great role in medical diagnosis, is characterized by
the vision, under the influence of iboga, of genies who during the course
of public divinatory sessions will reveal the nature of the affliction
suffered by the patient who has come for consultation.
In the
Ombwiri, we can note some similarity with Voodoo in the Caribbean and South
America.
Among the Mitsogho, the normative vision is that of the
whole tribe and corresponds in the initiate to the knowledge recorded
orally since in his childhood within the tribe. :
With the Fang, we
observe many differences because of the changes and turnovers that may have
taken place in the initiatory experience, the influence of Christianity and
the competition among various more or less orthodox messianic and prophetic
movements, and the loss of the tribal notion.
Some whites, most of
them French, have voluntarily gone through the trial of chewing of iboga. A
few of them were able to be interviewed. A study of the the interpretation
of these interviews is in progress at this time (O. Gollnhofer and R.
Sillans). Return to table of contents
Ibogaine in psychotherapy: psychoanalysis according to Naranjo (41)
Claudio Naranjo is a Chilean psychotherapeutic physician who,
while in training at the Institute of Personality and Research, University
of California at Berkeley, in 1969, published a remarkable report entitled
"Psychotherapeutic Possibilities of New Fantasy-Enhancing Drugs" in
Clinical Toxicology (Naranjo, C. 1969).41
Naranjo, in this
report, deals with the therapeutic action, at so-called subtoxic doses, of
two alkaloids, harmaline and ibogaine.
C. Naranjo wrote: "Because
of the lack of a systematic study of these drugs (harmaline and ibogaine),
from the simple standpoint of chemotherapy they were considered as toxic at
a certain dose.
The fact is that the
phenomena of harmaline and ibogaine intoxication are the points of greatest
interest insofar as psychological exploration and psychotherapy are
concerned.
Harmaline was isolated in 1841 by Goebel 22 from the seeds of a plant of the family
Malpighiaceae, Peganum harmala. It has also been extracted from another
South American Malpighia, Banisteriopsis caapi or yage.
Yage bark
is the principal ingredient of the beverage used by the Indians of the
region of the headwaters of the Amazon in connection with certain
divination rites and practices and it is known, according to research done
at the University of Chile, that this drug was central to the culture of
different Indian tribes as far back as the paleolithic period.
The
effects of harmaline and of ibogaine are practically unique among the
psychoactive drugs.
The best term to describe these effects is the
one used by William Turner, a yage specialist, oneirophrenia, to refer to
the states induced by drugs that differ from psychotomimetic states by the
absence of any psychotic symptom while sharing with the psychotic or
psychotomimetic experience the preeminence of a primary thought
process.
Harmaline and ibogaine are characterized in their
psychological effects by a state such that it involves a dream phenomenon
without loss of consciousness or change in the perception of the
environment or any illusions or formal deterioration of thought and without
depersonalization.
In a word, we can say that there is an
enhancement of fantasies which is remarkable in that it does not interfere
with the ego. Such fantasies are more like actual visions than common
everyday dreams.
In a study on the psychological effects of
harmaline performed in Chile in 1963-64 together with other Chilean
physicians and with Indian traditional therapists, Naranjo pointed out that
one of the most remarkable aspects of the fantasy is its great
consistency.
The themes or images that are evoked are mostly
archetypes, according to Jung's definition of the term, namely ancient
memories, generally common to all humans, buried in their collective
unconscious.
To cite Voltaire: "The world, according to Plato, was
composed of archetypal ideas that always remained deep in the brain."
Naranjo distinguishes between two sorts of archetypes:
The
mythical style similar to the dream of a lost treasure, a kind old man, an
ideal woman, a saint, an ideal community and various so-called noble
thoughts, and so on.
The instinctive style such as it may be
expressed in a fantasy with aggression, sex, bloody scenes of all sorts,
incest or other practices.
By their spontaneity, these waking
dream sequences are more extreme than any other reported by patients from
their usual dreams and do not resemble the visions on mescaline or LSD. In
fact, the effects of the two types of drugs seem to be poles part, those of
the common hallucinogens being a high and angelic domain of esthetic
sensations, of a lack of union with anything else, while the domain of the
oneirophrenics is that of Freud's subterranean world of animal impulse and
regression.
Naranjo gives some examples of subjects treated
successfully with harmaline at doses of 4-5 mg/kg orally (about 300
mg).
Concerning ibogaine, Naranjo says that he knows less than
about harmaline as regards the use of iboga by the Gabonese and Congolese.
He is unacquainted with the Bwiti and apparently does not know the
structure of ibogaine.
He knows that the drug has been used in the
European pharmacopeia for its antifatigue properties at a low dose, which,
according to him, is due to the fact that it is a MAOI.
As with
harmaline, Naranjo uses ibogaine at doses of 4-5 mg/kg orally and
one-quarter of it intravenously, and describes subjective reactions lasting
about 6 hours.
Compared with the effects of harmaline, those of
ibogaine appear less exotic. Even though the archetypal contents are common
to both (visions of animals being frequent), the quality of the fantasy is
generally more personal and concerns the subject himself, his parents and
significant others.
At the same time, the fantasy evoked by
ibogaine is easier for the subjects to manipulate, either on their own
initiative or through the psychotherapist, so that, more often than with
other drugs, they can stop to contemplate a scene, go back, explore an
alternative in a given sequence, bring a previous scene back to life,
etc.
This ease with which the events in a treatment with ibogaine
can be manipulated and the fact that the experience can be directed to the
desired area is probably one of the reasons for the success observed by
many psychotherapists who have used this drug.
Naranjo was much
more impressed by the effects obtained in an ibogaine session than with
those observed with any other drug.
An example really shows the
ease with which the psychotherapist is able to direct his analysis:
This is a young patient who, when treated with ibogaine, decides to lie
down and close his eyes shortly after feeling the effects of the
drug:
"First, he sees the face of his father, facing him as though
they were playing a game, with a restrained smile. His comment at this
point is that his father looks like a little boy to him. It was like
someone unfamiliar and yet familiar, like something the patient had
forgotten for many years.
Suddenly his father's features change,
distorted by rage. The scene changes and the patient sees a naked woman
hiding her face with her arm, afraid.
Close by, he sees his
father, also naked, throwing himself on the woman in a sexual attack. He
feels a controlled rage in the woman whom he now identifies as his
mother."
At that moment, Naranjo asks the subject to have his
father and mother engage in conversation, intending in this way to distance
the latent content of these images. "What is she saying?" "Go away"; "what
does he feel?" He cannot imagine. "I am perplexed", he suggests.
Naranjo then chooses another tack to make the subject's feelings more
conscious and explicit.
"Now, you be your father. Become your
father, to the best of your dramatic abilities, and listen to what he is
telling you."
Then, personifying his father, the patient falls,
not into perplexity, but into a great sadness, suffering and rejecting his
anguish.
Shortly after this episode, a drastic change occurred in
the way the subject viewed his parents and, consequently, in his feelings
toward them.
The next day, he commented that only now did he know
how much he identified with his mother, looking at things through her eyes,
blaming his father, and more than that, a man, which had interfered with
his own masculine aspirations.
In contrast to his usual
idealization of his mother in a total love and his perception of his father
as a selfish brute, he then had the feeling of knowing them as they
are.
He wrote: "I have seen my mother as a hard person, without
affection or fear, and I no longer look upon my father as an insensitive
being who had hurt her in his love affairs, but as someone who wishes to
open the door of his love, without succeeding. Now, I am full of compassion
for my mother."
Compared to the dramatic quality of psychedelic
experiences, this episode may appear insignificant or trivial, and yet it
was the key to a radical change in the attitudes of the young
patient.
That might be said of the experiences with ibogaine in
general, when we compare its effects with those of LSD.
Here, the
type of contact concerned by the unconscious material is symbolic (rather
than assuming the form of a free-floating emotion, as with LSD), and may
henceforth be assimilated in the form of lasting signs.
Such signs
generally occur when a fantasy or a hypothesis that had been unconscious
becomes conscious with such clarity that the ego of a mature person is
compelled to become aware of his or her deep-rooted former error.
Naranjo concludes as follows:
"I do not want to give the
impression that I regard ibogaine as a psychiatric panacea that will bring
changes by itself. I believe that many drugs may be used for psychological
exploration, but that these drugs can only be an instrument.
I
doubt that there is anything that can be achieved with a drug that cannot
be done without it. However, drugs can be psychological catalysts
that make it possible to compress a very lengthy psychotherapeutic process
into a shorter time and change its prognosis.
Although ibogaine cannot open a door by itself, it can be considered as
the oil for its hinges".
At the time of the publication of his
report on drugs that enhance fantasies, in June 1969, C. Naranjo, together
with a Frenchman, D.P.M. Bocher, obtained a special drug patent in France
pursuant to an application submitted on January 31, 1968 and issued on July
31, 1969, for:
"A new medication acting on the central nervous
system that can be used in psychotherapeutic treatments and as an antidrug
preparation".(Bocher, D.P. & Naranjo, C. 1969).5 The drug was composed of total alkaloids of
Tabernanthe iboga roots combined with an amphetamine in a proportion
varying according to the behavior of the patient.
Among the 50
cases studied in psychiatry, Naranjo described four in support of his
application for a "nontoxic drug that clarifies thoughts and permits a very
thorough introspection while preserving the patient's emotional character
which is indispensable for the stimulation of thought and
imagination."
However, in this same period, following the
resolutions of the World Health Assembly of May 1967 and May 1968, the
American federal government classified ibogaine, through the F.D.A., among
the substances analogous to lysergides and to certain CNS stimulants.
"Whereas, in the interest of public health, certain regulatory
provisions should be applied relating to the manufacture, transportation,
possession, sale and distribution, delivery and acquisition for valuable
consideration or free of charge of soporific and narcotic substances, and
of certain substances likely to produce drug dependency or endanger human
health".
These regulations are applicable to the following
substances, to their isomers, unless expressly exempted, to their salts,
ethers and esters, as well as to the salts of said ethers and esters in all
cases where such salts may exist.
The list of these substances
includes: amphetamines, ibogaine, compounds and derivatives of lysergic
acid, amides of lysergic acids and other derivatives, peyotl and mescaline
[harmaline is not mentioned], hallucinogenic mushrooms, psilocybin and
derivatives of dimethyltryptamine, 4-OH-DMT and 5-OH-DMT.
We shall
return later to this decree which was applicable beginning in 1970 in
several European countries, France and Belgium in particular.
The
fact is that in France and in Belgium, nothing more was heard about
ibogaine and the sale of Lambarène was prohibited.
Return to table of contents
Ibogaine for combatting drug dependencies according to Howard Lotsof (32,33,34,35,36,37)
In the early 1960s, a young American, Howard Lotsof, during the
course of a drug party with some friends, offered six of them the trial of
a single dose - about 500 mg - of ibogaine.
While interest in
ibogaine may have started with this drug party, the unique effects of
ibogaine became immediately evident in that it was not a substance
conducive to such parties. There followed a period of six months of lay
research which provided a dose-related response study ranging from 1 mg/kg
to 19 mg/kg of ibogaine in both addict and non-addict human subjects.
Five of Lotsof's seven friends gave up the use of drugs during these six
months. As for young Lotsof, who had permanently recovered, he rebuilt his
life, and although he was not a physician or a psychologist, he dreamed ("I
had a dream", he told us the first time we met, paraphrasing the minister
Dr. Martin Luther King), he dreamed that he would be the one who would
contribute to curing drug addicts by providing them ibogaine.
H. Lotsof
collected all the available documentation on iboga and ibogaine and, as a
good American and businessman, founded a New York corporation, NDA
International, Inc., whose purpose was partly a humanitarian mission and
partly the marketing of a proprietary pharmaceutical preparation, Endabuse,
composed of capsules of ibogaine hydrochloride.
In 1985, H. Lotsof
took out a U.S. Patent on a Rapid method for interrupting the narcotic
addiction syndrome,(Lotsof, H. 1985)36, followed by another one
in 1986 on a Rapid method for interrupting the cocaine and amphetamine
addiction syndrome (Lotsof, H. 1986)35 and subsequently yet
another in 1989 for a Rapid method for attenuating the alcohol dependency
syndrome.(Lotsof, H. 1989)34, and in 1991 for a Rapid method for
interrupting or attenuating the nicotine/tobacco dependency syndrome.37
The heroin addiction syndrome had been interrupted in 5
of the 7 subjects described in the first patent.
A single treatment with
ibogaine or ibogaine hydrochloride administered orally at a dosage ranging
from 6 mg/kg to 19 mg/kg made it possible to interrupt the use of heroin
for at least six months.
The duration of the
treatment is about 30 hours, and ibogaine exerts a stimulant effect during
this period. An abreactive process takes place during the treatment but
does not become evident until the patient awakens from a natural sleep that
occurs after the primary and secondary effects of ibogaine are
diminished.
The drug addicts no longer desire to take heroin and
show no perceptible signs of physical withdrawal. The subjects are relaxed
and express themselves coherently. They demonstrate a feeling of
self-confidence.
Lotsof describes the effects of the oral
administration of ibogaine and divides these effects into three stages,
comparable to the four stages of the Bwiti of the Mitsogho.
These
three stages are described perfectly in the interview by the journalist Max
Cantor 33 with a 44-year-old subject who had
been a cocaine addict for more than eight years and was treated by the
Lotsof procedure.
1st stage: 15 to 20 minutes after the
start of the treatment, a numbing of the skin is accompanied by an auditory
buzzing and an oscillating sound. Objects appear to vibrate
intensely.
The first visions appear after an hour. Suddenly, on
the walls, there appears a screen on which the subject views pictures that
may be archetypes, more or less deformed animals, an abyss lit up by
lightning, etc., or more personal episodes related either to childhood or
to more recent events.
The subject may question the persons he
sees, identify with one of them, be at the same time a spectator and an
actor. He views a film of his subconscious and his repressed memories. He
looks within himself.
2nd stage: 5 to 10 hours later,
the visions cease and cutaneous sensitivity begins to return. This stage is
marked by an unusually high energy that lasts 5 to 8 hours, during which
the subject see flashes of light around him. Then comes what the subject
calls the question-and-answer period. He analyzes the visions that he
remembers, seeks an interpretation and may communicate with the people
around him.
Ibogaine shows him where his problem is. He has the
impression that a reset button has been actuated. Everything is erased,
everything becomes sharp and clear. He knows where his life took the wrong
turn and what he must do to get back on the right path.
This
question-and-answer period may last 20 hours, during which the subject
remains under medical supervision.
3rd stage: the subject
remains awake from a residual stimulation for up to 20 hours and then goes
to sleep for as short a period as two hours and will wake up in top form,
provided he is young and his general health had been good previously, with
a new self-confidence, feeling no more need to take drugs.
Mr. Lotsof,
who knew of us, O. Gollnhofer, P. Potier (Member of the French Academy of
Sciences, Professor at the Museum of Natural History in Paris, Director of
the Institute of Chemistry of Natural Substances, C.N.R.S.,Gif-sur-Yvette,
91190 Essonne, France) and R. Goutarel, through his bibliographical
documentation, came to France and contacted us. We were able to get some
appointments, with Mr. Lotsof, at the Ministry of Health when Madame
Barzach was Minister. We must say that we were received with courtesy and
some skepticism. And then, Ministries change...
Our impression was
that the people we met with, still impressed with the failures of LSD, were
always afraid of making some mistake for which they would have been held
accountable.
And yet, around the same time, in Figaro Magazine of
February 14, 1987, there was a story on a shock treatment administered by
the Buddhist monks of ThamKrabok monastery in Thailand that resembles
uncannily what is observed during the chewing of iboga.
A
spectacular sequence presented to Madame Barzach and shown on television on
the program 7/7 hosted by Madame Sinclair was the vomiting of the patients
who, according to the commentator, had to get rid of the poisons in their
system. Unfortunately, the drug was being kept secret, and it was said that
Minister Chalandon had sent an observer over there to learn the secret.
That secret seems obvious to us, and we know Apocynaceous plants from Asia
containing ibogaine derivatives which, in all likelihood, have the same
oneirophrenic properties as the latter.
At this time, Mr. Lotsof,
who went to Gabon to collect a certain quantity of iboga, is having
experiments pursued in several countries. Excellent results are being
reported in the European and North American press. There have been several
interviews with subjects successfully treated by the Lotsof
procedure.
Thanks to him, basic research is
being conducted at Erasmus University of Rotterdam, at the Addiction
Research Foundation in Toronto, at Albany Medical College, N.Y., and
through the Committee on Problems of Drug Dependence of the N.I.H.,
Bethesda, Maryland, for the purpose of investigating the different body
systems, the CNS in particular, in which ibogaine is involved. Blockade of
morphine-induced stimulation of mesolimbic and striatal dopamine by
ibogaine has recently been demonstrated by the Albany Medical College
researchers.38
The 1967-68 resolutions
of the World Health Assembly classified ibogaine among the drugs capable of
producing dependency or impairing human health. When all is said
and done, this alkaloid had been found guilty of the charge of being a
hallucinogen similar to LSD, whose hazards for those who use it had
recently come to light.
The fact is, however, that even though
ibogaine is considered as a hallucinogen (oneirophrenic), it produces no
drug dependency and it has proved to suppress dependency to opiates,
amphetamines, cocaine, LSD and even alcohol and tobacco.
As for
"impairing human health", the Gabonese experience shows that this is simply
not true, quite the contrary.
The 1967-68 decree never did put an
end to the illegal trade in amphetamines (the famous Ecstasy pill), nor to
the trade in LSD. However, on that market, one never finds iboga or
ibogaine.
According to Dhahir (1971) 14, the
appearance of ibogaine on the illegal drug market was reported in 1967 by
the police of Suffolk County, N.Y., on a single occasion, when it was used
to dilute heroin, and after Haight Ashbury it was reportedly used by young
addicts in San Francisco as a substitute for LSD.
Ibogaine
suddenly disappeared from the market and it seems that the drug dealers
rapidly became aware of the fact that its use would deprive them of part of
their clientele. Return to table of contents
Conclusions
What are we to conclude from this three-phase
experience of the role of iboga (or ibogaine) at subtoxic doses, in the
Bwiti, in psychotherapy according to Naranjo, and finally in combatting
drug addiction?
1) In the Bwiti, and the Mitsogho Bwiti in
particular in which we must emphasize the rigorous rites and the motivation
inherent in it, the quantity of drug (scrapings of iboga root) is measured
by the "mother", the initiate who accompanies and constantly watches over
the initiate-to-be. It is measured in the number of baskets and cannot be
translated for us in weight of ibogaine. It is adjusted to the behavior of
the subject and makes it possible to go past the first stage to reach the
stage of so-called normative visions, corresponding to the real motivation
of he who aspires to see and to know the things of the beyond.
The
intoxication by iboga is slow and progressive, which makes it possible to
observe four stages during the visions. The first three stages are
essentially of the Freudian type and the fourth one, the so-called stage of
normative visions, corresponds to the collective image of the tribe.
Finally, the initiation into the Bwiti among the Mitsoghos concerns the
passage from adolescence to adulthood. Hence the necessity of eliminating
the epigenetic acquisitions from the period of childhood and adolescence in
order to reprogram in the young man a new ego in keeping with the cultural
norms of the tribe.
In the Bwiti of the Fang, the ceremony may be
accelerated by substituting for the scrapings of iboga a galenic
preparation flavored with milk, sugar or palm wine, known under the names
of "express" or "automatic".
Women can be initiated in the Fang
Bwiti, and many differences are observed due to the changes in the
initiatory experience that may have occurred under the influence of
Christianity and the competition among the various more or less orthodox
messianic and prophetic movements and the loss of the tribal notion.
Therefore, it is out of the question to speak of normative visions in the
Fang Bwiti, which is a real syncretism between ancestor worship and
Christianity. When all is said and done, the visions correspond to the
culture of the future initiate: Christian and Western culture for whites
who are initiated into the Fang Bwiti.
2) The doses of
ibogaine used in psychotherapy according to Naranjo are relatively low, and
the session does not last more than 6 hours. The dose of 300 mg orally
appears to be the minimum required for triggering the visions analyzed by
the psychotherapist who constantly guides the patients as he searches for
the deep-seated causes of the neurosis for which the patient has consulted
him. It appears that the sessions have to be repeated.
Naranjo's
conclusion is that ibogaine cannot produce the changes just by itself,
hence the need for a psychotherapist.
3) In the treatment
of drug addicts, H. Lotsof gives a single dose of about 1 g of ibogaine
hydrochloride orally.
The session is quite long, about 36 hours,
which is comparable to what is observed during the initiation into the
Bwiti, given that the slow chewing of iboga and the accompanying rites are
dispensed with. We might note that in the Fang Bwiti, the session also
lasts approximately 36 hours when the so-called "express" or "automatic"
galenic preparation is substituted for the iboga scrapings.
Thus,
the first visions appear 2 hours after the ingestion of ibogaine
hydrochloride. The three phases described by Lotsof are comparable to the
four phases of the Mitsogho Bwiti, the first phase being that of Freudian
type visions, and the second phase ("questions and answers") being
comparable to the phase of normative visions. Lotsof describes a third
phase, which is one of restorative sleep of short duration.
We
should point out that in all likelihood, the success of the Lotsof method
also depends on a deep motivation of the subject who is treated, which is
the will to eliminate all drug dependency.
On November 17, 1989,
the United States Senate Committee on the Judiciary published a Committee
Report on Pharmacotherapy for Illicit Drug Use.
This report deals
essentially with a research program, the Medication Development Program
(MDP) entrusted to the National Institute on Drug Abuse (NIDA) in
Rockville, Maryland.
Beginning in 1989, the Director of the MDP
was given a subsidy of 30 million dollars. Starting at the beginning of
1990, the research budget was increased to 200 million dollars. The
research, at the time, was not oriented toward developing a chemical
substance that might cure addicted persons, but toward substitution drugs
like methadone that remove the need for hard drugs, particularly cocaine,
while creating a less dangerous dependence.
At the time, ibogaine
had not been listed among the products of interest for combatting chemical
dependency.
It was difficult to accept the fact that a chemical
could, in a few days, suppress all dependency to opiates, cocaine or any
other drug.
There were then and there are still two opposing
schools of thought: the proponents of substitution chemical drugs and those
of gentle, long-lasting psychotherapy that could sometimes result in a
cure.
We can therefore understand that the method of H.S. Lotsof
was initially met with disbelief and even hostility.
Before
authorizing clinical trials for a new drug, the government agencies
responsible still require, quite appropriately, that its activity be
demonstrated in the animal.
In addition to
proving that ibogaine has a low toxicity14 and perhaps
potentiates the analgesic action of morphine32, the
pharmacodynamic studies in animals had supplied few data demonstrating the
incredible property of ibogaine to modify the behavior of an individual and
result in a new individuation of the brain by eliminating certain
tendencies detrimental to its full development.
However, new
techniques developed by researchers in the neurosciences have recently
provided some definite information as to the mechanism of action of
ibogaine in the treatment of addicts (morphine and cocaine).
Using
microdialysis, Di Chiara and Imperato (1988)15
reported that acute administration of amphetamine, cocaine, morphine,
nicotine and ethanol, all known to be addictive drugs, increases the
extracellular dopamine (DA) levels in the nucleus accumbens and to a lesser
extent in the striatum.
I.M. Maisonneuve (1991)38 showed that
ibogaine blocks the morphine-induced stimulation of mesolimbic and striatal
dopamine. Curiously, it appears that ibogaine affects brain DA systems for
a period of time that exceeds its elimination from the body and during this
time alters the responses of these systems to morphine. Furthermore,
ibogaine alters cocaine-induced accumbens dopamine neurotransmission
(Broderick, P.A., 1991).6
Ibogaine reduced
the cocaine-induced locomotor stimulation when given two hours before an
acute injection of cocaine to mice. This stimulation is also reduced when a
second injection of cocaine is given 24 hours later (H. Sershen,
1992).54
Finally, S.D. Glick (1991)21 demonstrated that ibogaine reduces the
intravenous self-administration of morphine in rats, not only in the hour
after ibogaine treatment (acute effect) but also one day or more later
(after-effect). Since ibogaine is eliminated rapidly14, the
persistence of this after-effect suggests the formation of a metabolite of
ibogaine with a long half-life.
Barrass, B.C. and Coult
(1972)2 had shown that ibogaine inhibits the oxidation of
serotonin by a monoamine oxidase (MAO), ceruloplasmin, and catalyzes the
oxidation of catecholamines by the same substrate.
Indeed, ibogaine is a potent serotoninergic that has
ability to reduce the level of cerebral catecholamines. This decrease in
the level of catecholamines, dopamine in particular, explains the results
described recently on the blockade of the stimulation of mesolimbic and
striatal dopamine induced by morphine or cocaine.
We should point
out that ibogaine is not specific to morphine and cocaine but is active in
the presence of all addictive drugs, which justifies the patent
applications that followed the initial patent of H.S. Lotsof.
The
decrease in the level of catecholamines and the joint increase in the
cerebral serotonin level result in a suppression of REM sleep and the
appearance of the hallucinatory phenomenon (C. Debru, 1990).12; LSD, like ibogaine, 2 is a
potent serotoninergic that inhibits the oxidation of serotonin and
catalyzes the oxidation of catecholamines by MAO.
However, there
is an enormous difference between these two alkaloids: LSD is active at
doses of less than a milligram. Its activity is difficult to control and
the hallucinatory phenomena produced belong to a high and angelic domain of
esthetic sensations, whereas ibogaine is hallucinogenic only at doses in
excess of 100 mg, and the domain of this oneirophrenic substance is that of
the subterranean world of Freud, of animal impulse and of regression.
The toxicity of ibogaine is very low, lower than that of aspirin, which
makes this alkaloid easy to use.
The initiated masters in the
Bwiti have an antidote that enables them to interrupt at any time the
course of the visions if, for any reason, the absorption of iboga were to
be actually life-threatening for the neophyte.
Let us note that
serotonin is the neurotransmitter of the cerebral parasympathetic system,
catecholamines being neurotransmitters in the cerebral orthosympathetic
system, and that the negative chronotropic and inotropic effects as well as
the arousal-producing action of ibogaine are nullified by atropine, an
acetylcholine antagonist, acetylcholine being the neurotransmitter of the
autonomic nervous system.
The long waking dream period that
follows the absorption of iboga or ibogaine at a subtoxic dose (or
oneirophrenic dose according to Naranjo) appears to be responsible for a
temporary destructuring of the ego, followed by its restructuring.
This hypothesis is consistent with the observations made by the
ethnologists in their studies of the Mitsogho Bwiti, and may be compared to
the hypotheses of Michel Jouvet and Sir Francis Crick (C. Debru, 1990)12 on the role of dreams in the programming and
deprogramming of basic behavior patterns, resulting in a new individuation
of the human brain.
Normally, the stages of wakefulness of the
human brain are: waking, NREM (slow wave or deep) sleep, PGO
(pontogeniculo-occipital) waves, and REM (rapid eye movement or
paradoxical) sleep. REM sleep is the period of dreams.
Michel
Jouvet and Sir Francis Crick consider PGO waves to be the principal coding
tool that acts at the cortical level in recording the genetic and
epigenetic acquisitions necessary for the individuation of the human
brain.
In addition, through random activation mechanisms, the PGO
waves eliminate from certain types of neuronal networks an informational
overload linked to pathological behavior. This is what C. Debru calls
"cleaning out the neuronal circuitry."
REM sleep apparently
undertakes a sorting out process among the "residues" stirred up by the PGO
wave sleep pattern and disposes of these residues during dreaming.
Michel Jouvet (letter of November 7, 1990) wrote: "The oneiric effects
observed in humans and which are produced by hallucinogens do not enable us
to approach the dream mechanisms directly, because it does appear that
these two phenomena cannot be linked together as one."
We know,
however, that the principal difference between dreams and hallucinations
resides in the way in which the stages of wakefulness are organized, with
the suppression of REM sleep and the intrusion of PGO waves in the arousal
(waking) stage and in NREM (or slow) sleep.
The new organization
becomes: waking (arousal) stage, stage of PGO waves, hallucination stage,
sleep stage, and it appears possible that hallucinatory manifestations, the
waking dream, eliminate "residues" stirred up by the PGO wave pattern in
the absence of REM sleep. Return to table of contents
Near Death Experiences
According to the Mitsogho, the initiate will
see the Bwiti only twice in his life: on the day of his initiation and on
the day of his death.
This means that the visions at the approach
of death, what are called near death experiences (NDE), are the same as
those termed normative visions.
We know that at the time of dying,
some individuals see their whole life pass before them. In those who are
"rescued from death", a spectacular transformation is observed. They no
longer fear death, they feel stronger, more optimistic, calmer, and
contemplate their life more positively.
Two Americans, the
psychiatrist Raymond Moody39 and the
cardiologist Michael B. Sabom 49 have been
particularly interested in the oneiric manifestations of NDE.
After a statistical study of 150 people "rescued from death", M.B. Sabom
established a chart of these manifestations.
Sabom
chart
Autoscopic phase
1. Subjective feeling of being
dead
2. Peace and well-being
3. Disembodiment
4. Visions of material objects and events
Transcendental
phase
5. Tunnel or dark zone
6. Evaluation of past life
7. Light
8. Access to a transcendental world
Entering in light
9. Encounter with other beings
10. Return to life
Most of these manifestations are to
be found in the Mitsogho Bwiti. Starting at the 3rd stage, a peaceful and
agreeable vision, disembodiment; the neophyte feels himself wrapped up by a
wind that carries him off to an unknown village without beginning or end; a
vision of two extraordinary Beings, Nzamba-Kana, the first man and Disumba,
the first woman on earth. The village is covered by sparks, then a
brilliant ball of light appears, the sun, and the moon and the stars. The
sun is transformed into a handsome youth, the Master of the World, and the
moon into a beautiful woman, his wife, the mother of his children, the
stars. The wind carries the initiate back to earth where he is reborn and
is greeted with joy and pride by the elders.
In the Fang Bwiti,
where we have a syncretism between the religion of the ancestors and
Christianity, it is difficult, because of many divergent forms, to describe
a coherent whole corresponding to the normative visions of the
Mitsoghos. Return to table of contents
Interviews with young Frenchmen
However, interviews with young whites from France who were willing
to go through the Fang Bwiti initiation trial show a set of visions
characteristic of their Western and generally Christian culture, which for
the most part fit in with Sabom's chart.
Thus, in the narration of
a young man named Christophe, after some personal Freudian type visions and
a few visions influenced by the Fang Bwiti, there is the following
description: an absolute white, an indescribable luminous blue, the joy and
perfection of blue, a cave and a cavernous sound, bright light entering
through the forehead like a third eye, things seen in the astral, the sight
of the spiritual world that cannot be seen with the body, a large sun
fueled by our particles, the light of which we are a part. Paradise that
can be reached only through the spirit. The awareness of an envelope
preventing him from joining the spiritual world, etc.
The visions,
both in the Mitsogho Bwiti and in the Fang Bwiti, seem to be dominated by
this impression of shining lights that we find at the second stage
described by H.S. Lotsof in his first patent36 (H.S.
Lotsof, U.S. Patent 4,499,096, Feb. 12, 1985).
After a first stage
characterized by Freudian type visions, the second stage is marked by a
high energy during which the subject sees lightning or brief flashes of
light that dance about him. During this period, thoughts continue that seem
to amplify the meaning of the visions seen during the primary phase. This
is the question-and-answer period described by one of the subjects treated
according to H.S. Lotsof.
What is important is that this luminous phase
of questions and answers is followed by a restorative sleep from which the
subject awakens in great form and with a new self-confidence.
Lotsof notes that the first three stages together last 24 to 48 hours or
longer, followed by only 3 to 4 hours of sleep. This reduced need for sleep
may continue for 1 to 4 months. The persistence of this long-term
effect is consistent with the hypothesis (I.M. Maisonneuve, 1991; S.D.
Glick, 1991) of a metabolite of ibogaine with a long half-life.
Some subjects treated according to Lotsof retain for a fairly long time
the impression of being under the influence of ibogaine.
A young
Dutch woman wrote: "I lost a great deal of interest in drugs in general,
because the effect of ibogaine goes far beyond their effect, though not
necessarily in a pleasant way", and "Up until four months after the
treatment, I kept experiencing colors and light very intensely."
The conclusion of the report that was written recently by this
25-year-old woman six months after a treatment with ibogaine shows that
this alkaloid produced a real change in what she calls her "addictive ego",
and also shows the necessity of having a strong motivation.
"Ibogaine was a mental process for me, a form of spiritual purification
and a truth serum in which I had to experience its results through time.
It's only now, after six months, that I can say I am not addicted anymore.
It takes time to admit that there is no way back. Ibogaine is not a
solution in itself, although it takes away withdrawal completely. Ibogaine
helps you to realize that all knowledge is available to cure yourself
through will power. It's up to you if you are ready to give up your
addictive ego.
The recent decision of the National Institute on
Drug Abuse (NIDA) to add ibogaine to the list of drugs whose activity in
the treatment of drug dependency is to be evaluated should prompt the
competent authorities in European countries to engage rapidly along the
same lines. This applies to France in particular, where research on iboga
and its alkaloids began at the end of the 19th century and has continued
well beyond the second half of the 20th century.
If we consider
all the pharmacodynamic and therapeutic investigations conducted on iboga
and ibogaine, we may conclude that this alkaloid, unjustly condemned as a
hallucinogen, is a key that opens the door of the fascinating realm of
today's neurosciences, and we should like to see the creation of a
multidisciplinary organization including ethnologists, medical doctors,
psychiatrists and psychologists, chemists, pharmacists and pharmacologists,
and even technical writers, so that we can get a definite opinion on the
psychotherapeutic properties of iboga and ibogaine, whose use must now take
place under the norms of pharmaceutical development and medical ethical
review. Return to table of contents
Bibliography
1. Baillon, H. 1889. Sur
l'oubouélè du Gabon (The Oubwele of Gabon). Bulletin
mensuel de la Société Linéenne de Paris vol.
1(98):782-783. return
2. Barras, B.C. and Coult, D.B. 1972. Effects
of some centrally-acting drugs on caeruloplasmin. Progress in
Brain Res. 36, 97-104 (1972). return
3. Bartlett, M.; Dickel, D.F.; Taylor, W.I.
1958. J. Amer. Chem. Soc. Vol. 80:126. return to chapter,
/ view molecule
4. Binet, J.; Gollnhofer, O.; Sillans, R.
1972. Cahiers d'Études africaines vol.
46(Xii/195):253. return
5. Bocher, D.P. and Naranjo, C. 1969. Nouveau
médicament agissant au niveau du SNC, anti-drogue (A New CNS-active
Medication for Use Against Drugs). Bulletin Officiel de la
Propriété Industrielle, No. 35, September 1, 1969 (Special
Drug Patent P.V. No. 138.081, No. 7131M, Int. Class. A 61k). return
6. Broderick, P.A.
and Phelan, T.T. 1991 (January 15). The African alkaloid ibogaine alters
cocaine-induced accumbens dopamine neurotransmission: in vivo voltametric
studies on the conscious brain. CPDD Abstract form. return
7. Bureau, R., La
religion d'Eboga. Essai sur le Bwiti fang (The Religion of Eboga. Essay on
the Fang Bwiti). Thesis, Paris V, 317 pp., 1972. return
8. Burckhardt,
C.A., Goutarel, R., Janot, M.M., and Schlittler, E., 1952. Helv. chim. Acta
35, 642. return
9. Closmenil, A. de. 1905. De l'iboga et
del'ibogaïne (Iboga and Ibogaine). Thesis for the Degree of
Doctor of Medicine, Paris. return
10. Crick, F. 1979. Réflexions sur le cerveau
(Reflections on the Brain). Pour la science Vol. 25(Nov.):168.
11. Dacosta, L.; Sulklaper, I; Naquet, R. 1980. Rev.
E.E.G. Neurophysiol. Vol. 10(1):105. return
12. Debru, C., 1990. Neurophysiologie du rêve
(The Neurophysiology of Dreams), Paris, Hermann, Edition des Sciences et
des Arts. return
13.
Delourme-Houdé, J. 1944. Contribution à l'étude de
l'iboga (Contribution to the study of iboga). Thesis for Doctor's Degree
(Pharmacy), Paris University; Ann. Pharm. Fr. Vol. 430, 1946. return
14. Dhahir, H.I. 1971. A
comparative study on the toxicity of ibogaine and serotonin. Thesis, Ph.D.
In Toxicology, Indiana University. return
15. Di Chiara, G. and Imperato, A. 1988. Drugs
abused by humans preferentially increase synaptic dopamine concentrations
in the mesolimbic system of freely moving rats. Proc. Nat. Acad. Sci. Vol.
85:5274 return
16. Dutheil, R. and Dutheil, B., L'Homme
superlumineux (The Superluminous Man), Sand Publ., 1990. return
17. Dybowski, J. and
Landrin, E. 1901. C.R. Acad. Sci. Vol. 133:748. return
18. Fromaget, M., 1986.
Contribution of the Mitsogho Bwiti to the Anthropology of the Imaginary: A
Case of Divinatory Diagnosis in Gabon, Anthropos 81, 87- 107. return
19. Gaignault, J.C. &
Delourme-Houdé, J. 1977. Les alcaloïdes de l'iboga (Iboga
alkaloids). Fitoterapia Vol. 48(6):243. return
20. Gershon, S. and Lang, W.J. 1962. Arch. Int.
Pharmacodyn. Vol. 135:31. return
21. Glick, S.D.; Rossman, K.; Steindorf, S.;
Maisonneuve, I.M.; Carlson, J.M. 1991. Effects and after-effects of
ibogaine on morphine self-administration in rats. European J. Pharmacol.
195(1991):341-345. return
22. Goebel, F. 1841. Ann. Vol. 38:363. return
23. Gollnhofer, O. &
Sillans, R. 1985. Usages rituels de l'iboga au Gabon (Ritual Uses of Iboga
in Gabon). Psychotropes Vol. 2(3):95-108. return
24. Gollnhofer, O. &
Sillans, R. 1983. L'Iboga, psychotrope africain (Iboga, an African
Psychotropic Agent). Psychotropes Vol. 1(1):11-27. return
25. Goutarel, R. 1954.
Recherches sur quelques alcaloïdes indoliques et leurs relations avec
le métabolisme du tryptophane et de la dihydroxy- phenylalanine
(Research on some indole alkaloids and their relations with the metabolism
of tryptophan and dihydroxyphenylalanine). Thesis, Doctor of Science
Degree, Paris. return to chapter
/ view molecule
26. Goutarel, R., Janot, M.M.,
Mathys, F., and Prelog, V., 1953. Structure de l'ibogaïne (The
structure of ibogaine), C.R. Acad. Sci. 237, 1718. return
27. Goutarel, R., Janot,
M.M., Prelog, V., and Taylor, W.I., 1950. Helv. chim. Acta 33, 150,
164. return
28. Haller,
A., and Heckel, E., 1901. Sur l'ibogaïne, principe actif d'une plante
du genre Tabernaemontana, originaire du Congo (Concerning ibogaine, the
active principle of a plant of the genus Tabernaemontana native to the
Congo C.R. Acad. Sci. 133:850-853. return
29.
Khuong-Huu, F., J.P. Leforestier, G. Maillard and R. Goutarel, 1978. C.R.
Acad. Sci. 270, 2070, 2072. return
30. Lambert, M., 1901. Sur l'action
physiologique de l'iboga (On the Physiological Action of Iboga), C.R. Soc.
Biol., 53:1096-1097. return
31. Lambert, M., 1902.
Sur les propriétés physiologiques de l'ibogaïne(On the
Physiological Properties of Ibogaine), Arch. int. Pharmacodynamie et
Thérapie, 10:101-120). return
32. Lotsof, H.S.
1990. Personal communication. 33. Lotsof, H.S.
1990. Personal communication. [The Max Cantor interviews have since been
published in the San Diego-based journal The Truth Seeker: 1990, Vol.
117(5):23-26]. return
34. Lotsof, H.S. 1989. U.S. Patent No. 4,857,523. return 35. Lotsof, H.S. 1986.
U.S. Patent No. 4,587,243. return
36. Lotsof, H.S. 1985. U.S. Patent No.
4,499,096. return 37.
Lotsof, H.S. 1991. U.S. Patent No. 5,026,697. return
38. Maisonneuve, I.M.;
Keller, R.W. Jr.; and Glick, S.D. 1991. Interactions ibogaine, a potential
anti-addictive agent, and morphine: an in vivo microdialysis study.
European J. Pharmacol. 199: 35-42. return
39. Moody, R.A.: Life After Life: The Investigation
of a Phenomenon, Survival of Bodily Death, Walker & Co., 1988. The
Light Beyond, Bantam, 1989. return
40. Mueller, J.M.; Schlittler, E.; Bein, H.J. 1952.
Experientia Vol. 8:338. return
41. Naranjo, C. 1969. Psychotherapeutic
possibilities of new fantasy- enhancing drugs. Clinical Toxicology Vol.
2(2):209. return
42. Neu, Henri (Father). 1885. Archives
générales des Pères du Saint-Esprit Vol.
148-B-i. return
43.
Phisalix, M.C. 1901. Action physiologique de l'ibogaïne (Physiological
action of ibogaine). C.R. Acad. Sci. Vol. 53:1077. return
44. Pouchet, G. and
Chevalier, J. 1905. Note sur l'action pharmacologique de l'ibogaïne.
Sur l'action pharmacodynamique de l'ibogaïne (Note on the
pharmacological action of ibogaine. On the pharmacodynamic action of
ibogaine) , Bull. Gén. de Thérapeutique. return
45. Prioux-Guyonneau, M.;
Rapin, J.R.; Wepierre, J. 1977. J. Pharmacol. Paris Vol.
8(3):383. return
46.
Raymond-Hamet & Vincent, D. 1960. C.R. Soc. Biol. Vol. 154:2223;
Raymond-Hamet; Vincent, D.; Parant, M. 1956. C.R. Soc. Biol. Vol.
150:1384; Vincent, D. & Séro, I. 1942. Travaux Membres
Soc. Chim. Biol. Vol. 24:1352.
47.
Raymond-Hamet 1946. C.R. Acad. Sci. Vol. 223:757; 1943. Bull. Soc. Chim.
Biol. Vol. 25:200; 1942. Bull. Soc. Chim. Fr. Vol. 9:620; 1941. C.R. Acad.
Sci. Vol. 212:768; 1940. C.R. Soc. Biol. Vol. 134:541; 1940. C.R. Soc.
Biol. Vol. 133:426; 1939. Arch. Int. Pharmacology Vol. 63:27. return
48. Raymond-Hamet 1941.
L'iboga, drogue défatigante mal connue (Iboga, a poorly known
antifatigue drug). Bull. Acad. Med. Vol. 124:243. return
49. Sabom, M.B.
Recollections of Death, Harper & Row, 1982. return <
br> 50. Schlittler, E.,
Burckhard, C.A., Gellert, E. 1953. Die Kalischmelze des Alkaloides Ibogain,
Helv. Chim. Acta 36:1337. return
51. Schneider, J.A. and Rinehart, R.K. 1957. Arch. Int.
Pharmacodyn. Vol. 110(1):92. return
52. Schneider, J.A. and Sigg, E.G. 1957. Ann. N.Y.
Acad. Sci. Vol. 66:765. return
53. Schneider, J.A. 1956. Experientia Vol.
12:323. return
54.
Sershen, H., Hashim, A., Harsing, L., Lajtha, A. Ibogaine antagonizes
cocaine-induced locomotor stimulation in mice. (In press. J. of Life
Sciences.)
55. Séro, I. 1944. Une
apocynacée d'Afrique équatoriale (An Apocynacea from
Equatorial Africa). Thesis, Doctor of Pharmacy, Toulouse. return
56. Vincent, D. and
Séro, I, 1942. Action inhibitrice de Tabernanthe iboga sur la
cholinestérase du sérum (The inhibitory action of Tabernanthe
iboga on serum cholinesterase), C.R. Soc. Biol. 136:612-614. return
57. Wurman, M. 1939.
Contribution à l'étude expérimentale et
thérapeutique d'un extrait de Tabernanthe manii d'origine gabonaise
(Contribution to the experimental and therapeutic study of an extract of T.
manii from Gabon). Thesis, Doctor of Medicine Degree, Paris. return
58. Zetler, G. &
Lessau, W. 1972. Pharmacology Vol. 8:235. return
return to top
Main |
What's new |
Search |
Science |
Opinion |
Literature |
Art |
Links |
Treatment |
Bookshop |
Feedback
WJ Gladstone (left), R Goutarel (front), Paris 1988
|